<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Olipudase alfa: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Olipudase alfa: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Olipudase alfa: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="139538" href="/d/html/139538.html" rel="external">see "Olipudase alfa: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="139622" href="/d/html/139622.html" rel="external">see "Olipudase alfa: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F57172602"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions including anaphylaxis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients treated with olipudase alfa have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during olipudase alfa administration. If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, discontinue olipudase alfa immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reactions, a desensitization procedure to olipudase alfa may be considered.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57227883"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Xenpozyme</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57172630"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Enzyme;</li>
<li>
                        Recombinant Human Acid Sphingomyelinase</li></ul></div>
<div class="block doa drugH1Div" id="F57211582"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f2afd706-e340-4615-b7dc-df733f40f225">Acid sphingomyelinase deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acid sphingomyelinase deficiency:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Consider premedication with antihistamines, antipyretics, and/or corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing weight: </b>For patients with a BMI ≤30 kg/m<sup>2</sup>, use actual body weight. For patients with BMI &gt;30 kg/m<sup>2</sup>, use adjusted body weight for dosage calculation; adjusted body weight = (actual height in meters)<sup>2</sup> × 30.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> Follow dose escalation regimen and maintenance phase dosing as described below. Doses are administered once every 2 weeks:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Olipudase Alfa Dose Escalation Regimen and Maintenance Phase Dosing</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">Dose number (week)</p></th>
<th align="left">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">1 (Week 0 [Day 1])</p></td>
<td align="left">
<p style="text-indent:0em;">0.1 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">2 (Week 2)</p></td>
<td align="left">
<p style="text-indent:0em;">0.3 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">3 (Week 4)</p></td>
<td align="left">
<p style="text-indent:0em;">0.3 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">4 (Week 6)</p></td>
<td align="left">
<p style="text-indent:0em;">0.6 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">5 (Week 8)</p></td>
<td align="left">
<p style="text-indent:0em;">0.6 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">6 (Week 10)</p></td>
<td align="left">
<p style="text-indent:0em;">1 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">7 (Week 12)</p></td>
<td align="left">
<p style="text-indent:0em;">2 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">8 and maintenance dosing (Week 14 and every 2 weeks thereafter)</p></td>
<td align="left">
<p style="text-indent:0em;">3 mg/kg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>If a dose is missed by ≥3 days after the originally scheduled dose, follow the dosing recommendations described below. Dosing recommendations differ for dose escalation regimens and maintenance phase regimens:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b> Olipudase Alfa Dosing Recommendations Following Missed Dose(s)<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left"></th>
<th align="left" colspan="3">
<p style="text-indent:0em;">Number of consecutive missed doses</p></th></tr>
<tr>
<th align="left"></th>
<th align="left">
<p style="text-indent:0em;">1 missed dose</p></th>
<th align="left">
<p style="text-indent:0em;">2 missed doses</p></th>
<th align="left">
<p style="text-indent:0em;">≥3 missed doses</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup> For first dose after missed dose(s), if dose to be administered is 0.3 or 0.6 mg/kg, administer that dose twice as per dose escalation regimen.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Dose(s) missed in escalation regimen</b></p></td>
<td align="left">
<p style="text-indent:0em;">Administer last tolerated dose, then resume dose escalation regimen 2 weeks later.<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;">Administer 1 dose below last tolerated dose, then resume dose escalation regimen 2 weeks later.<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;">Restart dose escalation regimen starting at 0.3 mg/kg.<sup>a</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Dose(s) missed in maintenance phase</b></p></td>
<td align="left">
<p style="text-indent:0em;">Administer maintenance dose.</p></td>
<td align="left">
<p style="text-indent:0em;">Administer 1 dose below the maintenance dose, then resume maintenance dosing 2 weeks later.</p></td>
<td align="left">
<p style="text-indent:0em;">Restart dose escalation regimen starting at 0.3 mg/kg.<sup>a</sup></p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dora drugH1Div" id="F57211591"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F57211592"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>ALT and/or AST above baseline and &gt;2 times ULN prior to next scheduled treatment:</b> Adjust dose (eg, repeat prior dose or reduce dose) or temporarily hold therapy until ALT and AST return to baseline.</p></div>
<div class="block doo drugH1Div" id="F57211593"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, or 3 obesity (BMI &gt;30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV infusion: </b>Calculate dosing weight for dose escalation regimen and maintenance phase dosing with the following formula:</p>
<p style="text-indent:-2em;margin-left:6em;">Adjusted body weight (kg) = (actual height in m)<sup>2</sup> × 30</p></div>
<div class="block dot drugH1Div" id="F57211594"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity or infusion-associated reaction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Severe (eg, anaphylaxis):</b> Discontinue infusion and initiate appropriate medical therapy. If patient is rechallenged, a desensitization procedure may be considered. If patient tolerates rechallenge infusion, may increase to reach approved recommended dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild to moderate:</b> Consider temporarily holding, slowing infusion rate, and/or reducing dose. If dose reduced, re-escalate by following dose escalation regimen and maintenance phase dosing.</p></div>
<div class="block doe drugH1Div" id="F57211590"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F57197132"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="139538" href="/d/html/139538.html" rel="external">see "Olipudase alfa: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage</b>
<b> guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing weight for dosage calculation dependent on BMI.</p>
<p style="text-indent:-2em;margin-left:6em;">BMI ≤30 kg/m<sup>2</sup>: Use actual body weight.</p>
<p style="text-indent:-2em;margin-left:6em;">BMI &gt;30 kg/m<sup>2</sup>: Use an adjusted body weight based on the following equation:</p>
<p style="text-indent:-2em;margin-left:8em;">Adjusted body weight (kg) = (actual height in meters)<sup>2 </sup>× 30</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b97c3b7c-32b7-4a6d-82b9-c0e39800f3e9">Acid sphingomyelinase deficiency, non-central nervous system manifestations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acid sphingomyelinase deficiency (ASMD), non-central nervous system manifestations:</b>
<b>Note: </b>Consider pretreatment with antihistamines, antipyretics, and/or corticosteroids prior to infusion to prevent infusion reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initiation and escalation: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;18 years: IV: Administer once every 2 weeks in increasing doses every 2 weeks as per the following table:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:left;">
<b>Olipudase Dose Escalation</b>
<b> for Ages &lt;18 Years</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Dose number</p></th>
<th align="left">
<p style="text-indent:0em;">Week</p></th>
<th align="left">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">1</p></td>
<td align="left">
<p style="text-indent:0em;">0</p></td>
<td align="left">
<p style="text-indent:0em;">0.03 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">2</p></td>
<td align="left">
<p style="text-indent:0em;">2</p></td>
<td align="left">
<p style="text-indent:0em;">0.1 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">3</p></td>
<td align="left">
<p style="text-indent:0em;">4</p></td>
<td align="left">
<p style="text-indent:0em;">0.3 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">4</p></td>
<td align="left">
<p style="text-indent:0em;">6</p></td>
<td align="left">
<p style="text-indent:0em;">0.3 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">5</p></td>
<td align="left">
<p style="text-indent:0em;">8</p></td>
<td align="left">
<p style="text-indent:0em;">0.6 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">6</p></td>
<td align="left">
<p style="text-indent:0em;">10</p></td>
<td align="left">
<p style="text-indent:0em;">0.6 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">7</p></td>
<td align="left">
<p style="text-indent:0em;">12</p></td>
<td align="left">
<p style="text-indent:0em;">1 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">8</p></td>
<td align="left">
<p style="text-indent:0em;">14</p></td>
<td align="left">
<p style="text-indent:0em;">2 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">9</p></td>
<td align="left">
<p style="text-indent:0em;">16</p></td>
<td align="left">
<p style="text-indent:0em;">3 mg/kg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: IV: Administer once every 2 weeks in increasing doses every 2 weeks as per the following table:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:left;">
<b>Olipudase Dose Escalation</b>
<b> for Ages ≥18 Years</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Dose number</p></th>
<th align="left">
<p style="text-indent:0em;">Week</p></th>
<th align="left">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">1</p></td>
<td align="left">
<p style="text-indent:0em;">0</p></td>
<td align="left">
<p style="text-indent:0em;">0.1 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">2</p></td>
<td align="left">
<p style="text-indent:0em;">2</p></td>
<td align="left">
<p style="text-indent:0em;">0.3 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">3</p></td>
<td align="left">
<p style="text-indent:0em;">4</p></td>
<td align="left">
<p style="text-indent:0em;">0.3 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">4</p></td>
<td align="left">
<p style="text-indent:0em;">6</p></td>
<td align="left">
<p style="text-indent:0em;">0.6 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">5</p></td>
<td align="left">
<p style="text-indent:0em;">8</p></td>
<td align="left">
<p style="text-indent:0em;">0.6 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">6</p></td>
<td align="left">
<p style="text-indent:0em;">10</p></td>
<td align="left">
<p style="text-indent:0em;">1 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">7</p></td>
<td align="left">
<p style="text-indent:0em;">12</p></td>
<td align="left">
<p style="text-indent:0em;">2 mg/kg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">8</p></td>
<td align="left">
<p style="text-indent:0em;">14</p></td>
<td align="left">
<p style="text-indent:0em;">3 mg/kg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance: </i>Infants, Children, and Adolescents: IV: 3 mg/kg/dose every 2 weeks; initiate 2 weeks after completion of escalation phase.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed doses:</i> If a dose is missed by ≥3 days after the originally scheduled dose, follow the recommendations in the missed dose recommendations table, depending on whether the patient is in the escalation or maintenance phase. IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Olipudase Alfa Missed Dose Recommendations<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left" rowspan="2"></th>
<th align="left" colspan="3">
<p style="text-indent:0em;">Number of consecutive missed doses</p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">1 missed dose</p></th>
<th align="left">
<p style="text-indent:0em;">2 missed doses</p></th>
<th align="left">
<p style="text-indent:0em;">3 missed doses</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>a</sup> For first dose after missed dose(s), if dose to be administered is 0.3 or 0.6 mg/kg, administer that dose twice as per dose escalation regimen.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Dose(s) missed in escalation phase</p></td>
<td align="left">
<p style="text-indent:0em;">Administer the last tolerated dose, then resume dose escalation.<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;">Administer 1 dose level below the last tolerated dose, then resume dose escalation per olipudase alfa dose escalation table.<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;">Administer 0.3 mg/kg for the first dose, then resume dose escalation from that dose level per olipudase alfa dose escalation table.<sup>a</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Dose(s) missed in maintenance phase</p></td>
<td align="left">
<p style="text-indent:0em;">Administer maintenance dose.</p></td>
<td align="left">
<p style="text-indent:0em;">Administer 1 dose level below the maintenance dose, then resume maintenance dosing.</p></td>
<td align="left">
<p style="text-indent:0em;">Administer 0.3 mg/kg for the first dose, then escalate dose from that dose level per olipudase alfa dose escalation table.<sup>a</sup></p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hypersensitivity or infusion-associated reaction:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild or moderate: </i>Consider temporarily holding or slowing the infusion rate and/or decreasing the dose. If dose is reduced, re-escalate following dose escalation table.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe (including anaphylaxis): </i>Immediately discontinue olipudase alfa and initiate appropriate medical treatment. Consider the risks and benefits of restarting olipudase alfa.</p></div>
<div class="block dorp drugH1Div" id="F57197147"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F57197165"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Baseline: </i></p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST &gt;2 × ULN: Repeat AST and ALT within 72 hours after the end of the infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>During therapy: </i></p>
<p style="text-indent:-2em;margin-left:4em;">AST or ALT above baseline and &gt;2 × ULN: Repeat prior dose or reduce one dose level, <b>or</b> temporarily withhold olipudase alfa until ALT and AST return to baseline.</p></div>
<div class="block arsc drugH1Div" id="F57258276"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reaction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Life-threatening <b>hypersensitivity reactions</b>, including <b>anaphylaxis </b>and <b>angioedema</b>, have been reported in adult and pediatric patients treated with olipudase alfa. <b>Infusion-related reaction</b> (IRR; including acute phase reaction [APR]) has also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non–dose-related; immunologic; IgE mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; IgE-mediated reactions generally occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552'])">Ref</a></span>). IRRs typically occur within 12 to 72 hours postinfusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35471153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35471153'])">Ref</a></span>). In clinical trials, most APRs occurred 48 hours postinfusion during the dose escalation period.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid infusion rates</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F57180487"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and/or pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: C-reactive protein increased</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis and angioedema), infusion-related reaction (including acute phase reaction-like symptoms [including decreased serum iron; elevations of calcitonin and IL-6])</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Swelling at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue, headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Ocular hyperemia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, pharyngeal edema, pharyngitis, rhinitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, papule of skin</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, throat irritation</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Immunologic: Antibody development</p></div>
<div class="block coi drugH1Div" id="F57172604"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F57211566"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated transaminases: May cause elevated ALT and/or AST within 24 to 48 hours following infusion; monitoring required. Elevated ALT and AST generally returned to preinfusion concentrations at the time of the next scheduled infusion.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F57197108"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Treatment-related serious adverse reactions, anaphylaxis, hypersensitivity reactions, and infusion-associated reactions occurred more often in pediatric patients as compared to adult patients. Pediatric patients were also more likely than adult patients to experience non-serious adverse reactions including fever, cough, rhinitis, urticaria, diarrhea, nausea, vomiting, and abdominal pain.</p></div>
<div class="block foc drugH1Div" id="F57227884"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xenpozyme: Olipudase alfa-rpcp 4 mg (1 ea); Olipudase alfa-rpcp 20 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F57229464"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57509863"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Xenpozyme Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $1,748.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $8,741.81</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F57211609"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Cardiopulmonary resuscitation equipment should be readily available during administration. Treatment should be in direct consultation with a physician knowledgeable in the management of acid sphingomyelinase deficiency. Prior to administration, inspect for foaming; if foaming is present, allow to dissipate prior to administration. Use an inline, low protein-binding 0.2-micron filter during administration. Use polyurethane or PVC DEHP-free for infusion sets and polyethersulfone or polytetrafluoroethylene for inline filters. Use infusion rates as described below, starting with the rate listed under "Step 1." In the absence of infusion-associated reactions, increase infusion rate every 20 minutes sequentially through the remaining steps. At the end of the infusion, flush the infusion line with NS at the rate used for the last part of the infusion:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Olipudase Alfa Infusion Rates</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">Dose</p></th>
<th align="left" colspan="4">
<p style="text-indent:0em;">Infusion rate</p></th></tr>
<tr>
<th align="left"></th>
<th align="left">
<p style="text-indent:0em;">Step 1 (20 minutes)</p></th>
<th align="left">
<p style="text-indent:0em;">Step 2 (20 minutes)</p></th>
<th align="left">
<p style="text-indent:0em;">Step 3 (20 minutes)</p></th>
<th align="left">
<p style="text-indent:0em;">Step 4 (remainder of infusion time)</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">0.1 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">20 mL/hour</p></td>
<td align="left">
<p style="text-indent:0em;">60 mL/hour</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">0.3 to 3 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">3.33 mL/hour</p></td>
<td align="left">
<p style="text-indent:0em;">10 mL/hour</p></td>
<td align="left">
<p style="text-indent:0em;">20 mL/hour</p></td>
<td align="left">
<p style="text-indent:0em;">33.33 mL/hour</p></td></tr></tbody></table></div>
<div class="block admp drugH1Div" id="F57197198"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Cardiopulmonary resuscitation equipment should be readily available during administration. Treatment should be in direct consultation with a physician knowledgeable in the management of acid sphingomyelinase deficiency (ASMD). Prior to administration, inspect for foaming; if foaming present, allow to dissipate prior to administration. Use an in-line low protein-binding 0.2 micron polyethersulfone or polytetrafluoroethylene filter and polyurethane or PVC DEHP-free infusion sets during administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Neonates, Infants, Children, and Adolescents &lt;18 years: Infuse at rates described in the table, depending on olipudase alfa dose. Infusion rates are in <b>mg per kg </b>per hour.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Olipudase Alfa Infusion Rate for Ages &lt;18 Years</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Dose</p></th>
<th align="left">
<p style="text-indent:0em;">Infusion rate</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">0.03 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">Infuse at 0.1 mg/kg/hour for the full length of the infusion.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">0.1 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">Infuse at 0.1 mg/kg/hour for 20 minutes, then increase to 0.3 mg/kg/hour for the remainder of the infusion.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">0.3 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">Infuse at 0.1 mg/kg/hour for 20 minutes, then increase to 0.3 mg/kg/hour for 20 minutes, then increase to 0.6 mg/kg/hour for the remainder of the infusion.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥0.6 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">Infuse at 0.1 mg/kg/hour for 20 minutes, then increase to 0.3 mg/kg/hour for 20 minutes, then increase to 0.6 mg/kg/hour for 20 minutes, then increase to 1 mg/kg/hour for the remainder of the infusion.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Adolescents ≥18 years: Infuse at rates described in the table, depending on olipudase alfa dose. Infusion rates are in <b>mL</b> per hour.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Olipudase Alfa Infusion Rate for Ages ≥18 Years</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Dose</p></th>
<th align="left">
<p style="text-indent:0em;">Infusion rate</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">0.1 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">Infuse at 20 <b>mL</b>/hour for 20 minutes, then increase to 60 <b>mL/</b>hour for the remainder of the infusion.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥0.3 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">Infuse at 3.3 <b>mL</b>/hour for 20 minutes, then increase to 10 <b>mL/</b>hour for 20 minutes, then increase to 20 <b>mL</b>/hour for 20 minutes, then increase to 33.33 <b>mL</b>/hour for the remainder of the infusion.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Maintenance doses may be infused at home in patients who tolerate their infusion well, based on physician evaluation and recommendation. Doses and infusion rates should remain constant and cannot be changed without physician supervision; if a dose is missed or delayed, contact physician.</p></div>
<div class="block hazard drugH1Div" id="F57211568"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Olipudase alfa may cause teratogenicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F57172603"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Acid sphingomyelinase deficiency:</b> Treatment of non-CNS manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.</p></div>
<div class="block cyt drugH1Div" id="F57229852"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57229849"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F57211561"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation in patients who could become pregnant.</p>
<p style="text-indent:0em;">Patients who may become pregnant should use effective contraception during therapy and for 14 days after the last dose of olipudase.</p></div>
<div class="block pri drugH1Div" id="F57211562"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies with exposures less than the maximum recommended human dose, in utero exposure to olipudase may cause fetal harm.</p>
<p style="text-indent:0em;">Treatment with olipudase should not be initiated or escalated during pregnancy. The decision to continue treatment if pregnancy occurs during olipudase therapy should be individualized.</p></div>
<div class="block brc drugH1Div" id="F57211563"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if olipudase is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F57211611"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Pregnancy status (prior to treatment initiation in patients who could become pregnant); ALT and AST (within 1 month prior to initiation of therapy; within 72 hours prior to dose escalation; prior to next scheduled dose when resuming treatment following a missed dose; within 72 hours after the end of the infusion if the baseline or preinfusion ALT/AST is &gt;2 times ULN; as clinically indicated during maintenance therapy). Consider IgE anti-drug antibody (ADA) in patients who experience hypersensitivity reactions and serum tryptase and complement activation in patients who experience anaphylaxis.</p></div>
<div class="block pha drugH1Div" id="F57211571"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As an exogenous source of the enzyme acid sphingomyelinase (ASM), olipudase alfa degrades sphingomyelin to ceramide and phosphocholine. Olipudase alfa is not expected to cross the blood-brain-barrier or address CNS manifestations of ASM deficiency (ASMD).</p></div>
<div class="block phk drugH1Div" id="F57197110"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Exposures are lower in pediatric patients compared with adults (Diaz 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 13 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Unknown; expected to be metabolized into small peptides and amino acids by catabolic pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Adults: 32 to 38 hours.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olipudase-alfa-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33875845">
<a name="33875845"></a>Diaz GA, Jones SA, Scarpa M, et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency. <i>Genet Med</i>. 2021;23(8):1543-1550. doi: 10.1038/s41436-021-01156-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olipudase-alfa-drug-information/abstract-text/33875845/pubmed" id="33875845" target="_blank">33875845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention (CDC); National Institute for Occupational Safety and Health (NIOSH). NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed September 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35471153">
<a name="35471153"></a>Wasserstein M, Lachmann R, Hollak C, et al. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: one-year results. <i>Genet Med</i>. 2022;24(7):1425-1436. doi:10.1016/j.gim.2022.03.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olipudase-alfa-drug-information/abstract-text/35471153/pubmed" id="35471153" target="_blank">35471153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xenopozyme.1">
<a name="Xenopozyme.1"></a>Xenopozyme (olipudase alfa) [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 139537 Version 37.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
